BIEGi-1 

BIEGi-1 is an EGFR inhibitor. BIEGi-1 effectively disrupts the EGFR-Rheb interaction in cells. BIEGi-1 robustly inhibits EGFR kinase activity (reduces p-Y1068-EGFR) as well as mTORC1 activation (reduces p-T389-S6K1) in EGFR-mutant cells. BIEGi-1 shows strong antiproliferative effects on EGFR-mutant PC9 and HCC827 cells with IC₅₀ values of 17 nM and 20 nM, respectively. BIEGi-1 can be used for the study of cancers harboring EGFR mutations, such as non-small cell lung cancer (NSCLC)^[1].

BIEGi-1 (25 nM, 12 h) 在 PC9 细胞 (EGFR 突变) 中有效破坏 EGFR 与 Rheb 之间的相互作用^[1]。
BIEGi-1 (25 nM, 12 h) 在 EGFR 突变的 PC9 和 HCC827 细胞中强效抑制 EGFR 激酶活性 (降低 p-Y1068-EGFR) 以及 mTORC1 激活 (降低 p-T389-S6K1)^[1]。
BIEGi-1 (0.01-10000 nM, 72 h) 对 PC9 和 HCC827 细胞表现出强效的抗增殖作用，IC₅₀ 分别为 17 nM 和 20 nM^[1]。
BIEGi-1 (200 nM, 24 h) 在血清饥饿的 HEK-293T 细胞中，抑制由溶酶体定位的 LAMP2-V5-EGFR-TKD (野生型和激酶失活型) 诱导的 mTORC1 激活^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

615.72

C₃₆H₃₇N₇O₃

1429497-30-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. He X, et al. Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1. Cell Res. 2025 Jul;35(7):497-509.  [Content Brief]